MX2016007179A - Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. - Google Patents

Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.

Info

Publication number
MX2016007179A
MX2016007179A MX2016007179A MX2016007179A MX2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A MX 2016007179 A MX2016007179 A MX 2016007179A
Authority
MX
Mexico
Prior art keywords
treatment
biomarkers
methods
predictors
clinical sensitivity
Prior art date
Application number
MX2016007179A
Other languages
English (en)
Spanish (es)
Inventor
William Burnell Trotter Matthew
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016007179A publication Critical patent/MX2016007179A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2016007179A 2013-12-06 2014-12-05 Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras. MX2016007179A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913046P 2013-12-06 2013-12-06
PCT/US2014/068767 WO2015085160A2 (en) 2013-12-06 2014-12-05 Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies

Publications (1)

Publication Number Publication Date
MX2016007179A true MX2016007179A (es) 2016-09-08

Family

ID=53274284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007179A MX2016007179A (es) 2013-12-06 2014-12-05 Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.

Country Status (12)

Country Link
US (1) US20160312292A1 (enExample)
EP (1) EP3077547A4 (enExample)
JP (1) JP2017503481A (enExample)
KR (1) KR20160090390A (enExample)
AU (1) AU2014360316A1 (enExample)
BR (1) BR112016012792A2 (enExample)
CA (1) CA2932266A1 (enExample)
EA (1) EA201691143A1 (enExample)
IL (1) IL245936A0 (enExample)
MX (1) MX2016007179A (enExample)
PH (1) PH12016501023A1 (enExample)
WO (1) WO2015085160A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077058A2 (en) 2013-11-08 2015-05-28 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
BR112016012795A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
WO2016060557A1 (en) * 2014-10-17 2016-04-21 Stichting Maastricht Radiation Oncology "Maastro-Clinic" Image analysis method supporting illness development prediction for a neoplasm in a human or animal body
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
EP3347717A4 (en) 2015-09-11 2019-06-05 The Brigham and Women's Hospital, Inc. PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS
CA2999179A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
WO2017120446A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US20200270703A1 (en) * 2017-09-29 2020-08-27 Kyushu University, National University Corporation Method and kit for predicting therapeutic effectiveness of chemotherapy for diffuse large b-cell lymphoma patients
MX2022004688A (es) * 2019-10-21 2022-05-10 Celgene Corp Métodos para tratar un cáncer hematológico y uso de biomarcadores compañeros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-mor folinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona.
WO2024258819A1 (en) * 2023-06-15 2024-12-19 The Broad Institute, Inc. Neoplastic cytotoxicity induced by glycosylation
FR3158744A1 (fr) * 2024-01-30 2025-08-01 Universite Grenoble Alpes Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964354B2 (en) * 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
EP2544687A1 (en) * 2010-03-12 2013-01-16 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
MX353482B (es) * 2011-04-29 2018-01-16 Celgene Corp Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.

Also Published As

Publication number Publication date
WO2015085160A3 (en) 2015-07-30
WO2015085160A2 (en) 2015-06-11
BR112016012792A2 (pt) 2017-08-08
US20160312292A1 (en) 2016-10-27
AU2014360316A1 (en) 2016-06-16
EP3077547A2 (en) 2016-10-12
EP3077547A4 (en) 2017-11-08
KR20160090390A (ko) 2016-07-29
PH12016501023A1 (en) 2016-07-04
IL245936A0 (en) 2016-07-31
EA201691143A1 (ru) 2016-11-30
CA2932266A1 (en) 2015-06-11
JP2017503481A (ja) 2017-02-02

Similar Documents

Publication Publication Date Title
MX2016007179A (es) Metodos para el tratamiento de canceres hematologicos, y el uso de biomarcadores como predictores de la sensibilidad clinica frente a las terapias inmunomoduladoras.
MX2014009256A (es) Dispositivos de recogida de muestras con agentes de estabilizacion sanguinea.
BR112015022496A2 (pt) dispositivo de limpeza de instrumento médico
SA521430032B1 (ar) Vista أجسام مضادة لـ وأجزاء منها
MX2021001659A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
TR201907737T4 (tr) Test numunesi desteği ve çarpışma testi aparatı ve destek kullanılarak yapısal elemanın çarpışma testi yöntemi.
MX2015012646A (es) Verificacion de ubicacion de factores multiples.
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
TWD170683S (zh) 用於樣品採集裝置之均質化蓋件
BR112018003969A2 (pt) plataforma de aplicativo de célula pequena
TWD189982S (zh) 注射裝置的容器
AR082388A1 (es) Metodo para identificar un compuesto que tiene un efecto antiarritmico asi como los usos relacionados con el mismo
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
PE20161120A1 (es) Aparato y metodos de registro de hoyo
MY178540A (en) A surface feature manager
CL2015002482A1 (es) Estimación de las propiedades de un material.
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
MX2018014702A (es) Métodos para predecir el beneficio terapéutico de la terapia con anti-cd19 en pacientes.
BR112015017563A2 (pt) dispositivo de acesso vascular para inserção reprodutível de uma cânula para uma local de punção
EA201401201A1 (ru) Способ
BR112014027490A2 (pt) método de detecção eletroquímica
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
MX363679B (es) Metodo para diagnosticar cancer.
MX2015015023A (es) Metodo para la determinacion de cobre libre.